AbbVie deepens immunology push with $10.9bn Apogee swoop
AbbVie (ABBV) has agreed to buy Apogee Therapeutics (APGE) for $10.9bn, its largest acquisition in more than five years, as the pharmaceutical group looks to strengthen its pipeline of treatments for inflammatory diseases such as atopic…
